The clinical significance of the progression-free survival benefit seen with Merck & Co. Inc./Ariad Pharmaceuticals Inc.’s investigational sarcoma treatment Taltorvic (ridaforolimus) is likely to be a key discussion point for FDA’s Oncologic Drugs Advisory Committee during its March 20 review of the mTOR inhibitor.
Ridaforolimus was associated with a median PFS benefit of three weeks in its pivotal trial, an advantage that FDA reviewers and ODAC members may look upon skeptically given the recent...